相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
Hussein A. Tawbi et al.
NEURO-ONCOLOGY (2021)
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases
Anna Maria Di Giacomo et al.
CLINICAL CANCER RESEARCH (2021)
Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) treated with systemic therapy: A systematic literature review (SLR) and meta-analysis.
Hussein Abdul-Hassan Tawbi et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
Evan J. Lipson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Melanoma brain metastases - Interdisciplinary management recommendations 2020
Ralf Gutzmer et al.
CANCER TREATMENT REVIEWS (2020)
Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control
Christopher Alvarez-Breckenridge et al.
ONCOLOGIST (2019)
The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis
Eliana Rulli et al.
CANCER (2019)
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial
Harriet M. Kluger et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies et al.
LANCET ONCOLOGY (2017)
Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study
Daniel N. Cagney et al.
NEURO-ONCOLOGY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeted Therapies for Melanoma Brain Metastases
Anna S. Berghoff et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2017)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Response assessment criteria for brain metastases: proposal from the RANO group
Nancy U. Lin et al.
LANCET ONCOLOGY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
Paul W. Sperduto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
Prognostic Factors for Survival in Melanoma Patients With Brain Metastases
Michael A. Davies et al.
CANCER (2011)
Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
O. Amit et al.
EUROPEAN JOURNAL OF CANCER (2011)
Lessons learned from independent central renew
R. Ford et al.
EUROPEAN JOURNAL OF CANCER (2009)
分享论文
